JP2022507741A5 - - Google Patents

Info

Publication number
JP2022507741A5
JP2022507741A5 JP2021527208A JP2021527208A JP2022507741A5 JP 2022507741 A5 JP2022507741 A5 JP 2022507741A5 JP 2021527208 A JP2021527208 A JP 2021527208A JP 2021527208 A JP2021527208 A JP 2021527208A JP 2022507741 A5 JP2022507741 A5 JP 2022507741A5
Authority
JP
Japan
Prior art keywords
antigen
seq
binding site
antibody
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021527208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507741A (ja
JP7271666B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062011 external-priority patent/WO2020106620A1/en
Publication of JP2022507741A publication Critical patent/JP2022507741A/ja
Publication of JP2022507741A5 publication Critical patent/JP2022507741A5/ja
Priority to JP2023072027A priority Critical patent/JP7587629B2/ja
Application granted granted Critical
Publication of JP7271666B2 publication Critical patent/JP7271666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021527208A 2018-11-19 2019-11-18 アンタゴニストｃｄ４０モノクローナル抗体およびその使用 Active JP7271666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023072027A JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストｃｄ４０モノクローナル抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769514P 2018-11-19 2018-11-19
US62/769,514 2018-11-19
PCT/US2019/062011 WO2020106620A1 (en) 2018-11-19 2019-11-18 Antagonistic cd40 monoclonal antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072027A Division JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストｃｄ４０モノクローナル抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2022507741A JP2022507741A (ja) 2022-01-18
JP2022507741A5 true JP2022507741A5 (enExample) 2022-11-01
JP7271666B2 JP7271666B2 (ja) 2023-05-11

Family

ID=68848451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527208A Active JP7271666B2 (ja) 2018-11-19 2019-11-18 アンタゴニストｃｄ４０モノクローナル抗体およびその使用
JP2023072027A Active JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストｃｄ４０モノクローナル抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023072027A Active JP7587629B2 (ja) 2018-11-19 2023-04-26 アンタゴニストｃｄ４０モノクローナル抗体およびその使用

Country Status (20)

Country Link
US (7) US11261258B2 (enExample)
EP (1) EP3883652A1 (enExample)
JP (2) JP7271666B2 (enExample)
KR (1) KR102627246B1 (enExample)
CN (2) CN116003608B (enExample)
AR (1) AR117091A1 (enExample)
AU (2) AU2019385331B2 (enExample)
BR (1) BR112021009140A2 (enExample)
CA (1) CA3120358C (enExample)
CL (1) CL2021001230A1 (enExample)
CO (1) CO2021007691A2 (enExample)
EA (1) EA202191359A1 (enExample)
IL (1) IL283104B2 (enExample)
MX (1) MX2021005565A (enExample)
MY (1) MY204740A (enExample)
PE (1) PE20211293A1 (enExample)
SG (1) SG11202104776VA (enExample)
TW (1) TWI800694B (enExample)
WO (1) WO2020106620A1 (enExample)
ZA (1) ZA202103353B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20230331860A1 (en) * 2020-08-25 2023-10-19 Bristol-Myers Squibb Company Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2023274007A1 (zh) * 2021-06-29 2023-01-05 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
US20240343817A1 (en) * 2021-07-14 2024-10-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof
WO2023186111A1 (zh) * 2022-04-02 2023-10-05 和铂医药(上海)有限责任公司 一种靶向cd40的抗原结合蛋白及其制备和应用
CN117264063B (zh) * 2023-03-22 2024-04-23 赛业（苏州）生物科技有限公司 一种抗gpc3抗体及其应用
CN119490596B (zh) * 2023-08-21 2026-01-23 菲鹏生物股份有限公司 一种抗人IgM抗体及其应用
KR20250116195A (ko) * 2024-01-24 2025-08-01 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB2353887B (en) 1999-09-04 2003-09-24 Ibm Speech recognition system
WO2003028809A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Methods of therapy for b-cell malignancies
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
SI1682177T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
KR101128777B1 (ko) * 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
US20150315284A1 (en) 2004-11-09 2015-11-05 Xencor, Inc. OPTIMIZED Fc VARIANTS
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
EP2125893A2 (en) 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2155789B1 (en) 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
WO2012046745A1 (ja) 2010-10-04 2012-04-12 独立行政法人理化学研究所 Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2016023875A1 (en) * 2014-08-14 2016-02-18 F. Hoffmann-La Roche Ag Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
KR20250004095A (ko) 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
CN107810198B (zh) * 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
BR112017027549A2 (pt) * 2015-06-29 2018-09-11 Bristol-Myers Squibb Company anticorpo para cd40
BR112018006251A2 (pt) 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
KR20190057083A (ko) 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
US20200095323A1 (en) 2017-03-20 2020-03-26 The General Hospital Corporation MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
US20200148779A1 (en) 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions

Similar Documents

Publication Publication Date Title
JP2022507741A5 (enExample)
US11667722B2 (en) Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US20220267476A1 (en) Multispecific antibody constructs
KR102143506B1 (ko) 변형된 단백질 및 펩티드
RU2604196C2 (ru) Антитела против cd70
JP6746564B2 (ja) Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用
US10144782B2 (en) Humanized antibodies against CD269 (BCMA)
CN103946240B (zh) 对人ox40具有特异性的抗体分子
TWI280980B (en) Human antibodies that bind human IL-12 and methods for producing
TWI689518B (zh) 特異性結合人ｉｌ-１７ａ的分離的單株抗體
ES2923143T3 (es) Anticuerpos monoclonales antagonistas contra CD40 y sus usos
CN103154029B (zh) 抗人tweak的抗体及其用途
JP2014513953A5 (enExample)
JP2022093640A (ja) 抗ｉｌ－１治療に関する新しい適応症
JP2020509756A5 (enExample)
KR20170023212A (ko) 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
TW200831533A (en) Interleukin-13 binding proteins
JP2020521458A5 (enExample)
JP2014530611A5 (enExample)
JP2014511844A5 (enExample)
EP4536704A2 (en) Igf1r antibodies
TH2101002815A (th) โมโนโคลนอลแอนติบอดีที่เป็นแอนทาโกนิสท์ต่อ cd40 และการใช้แอนติบอดีดังกล่าว
NZ777121B2 (en) Antagonistic cd40 monoclonal antibodies and uses thereof
NZ777121A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
WO2023025309A1 (zh) 一种cdc平台抗体